Belgium
ABSCINT is a Belgium-based startup specializing in advanced in vivo imaging diagnostics, with a focus on developing innovative PET tracers using single-domain antibodies (sdAbs) for precision targeting. Their primary product is a specific anti-HER2 PET tracer, offering comprehensive whole-body imaging for evaluating disease heterogeneity in HER2-low and HER2-positive breast cancer. This non-invasive technology provides rapid imaging results within 90 minutes, with minimal radiation exposure. Additionally, it opens the door to HER2 reclassification via image-guided biopsies, thereby enhancing diagnostic accuracy, patient care, and treatment efficacy monitoring.
The company, founded in 2020, operates in the Biotechnology and Health Care industries. Despite lacking public information on their latest investment round and investors, ABSCINT's innovative approach to precision diagnostics through antibody scintigraphy showcases promising potential in the evolving landscape of medical imaging and cancer diagnostics.
